Literature DB >> 18446325

Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats.

L B M Resstel1, S F Lisboa, D C Aguiar, F M A Corrêa, F S Guimarães.   

Abstract

RATIONALE: Conditioned fear to context causes freezing and cardiovascular changes in rodents and has been used to measure anxiety. It also activates the dorsolateral column of the periaqueductal gray (dlPAG). Microinjections of cannabinoid agonists into the dlPAG produced anxiolytic-like effects in the elevated plus maze, but the effects of these treatments on fear conditioning remains unknown.
OBJECTIVE: The objective of this study was to verify if intra-dlPAG injection of the CB1 cannabinoid receptor agonist anandamide (AEA) or the anandamide transport inhibitor AM404 would attenuate behavioral (freezing) and cardiovascular (increase of arterial pressure and heart rate) responses of rats submitted to a contextual fear-conditioning paradigm.
MATERIALS AND METHODS: Male Wistar rats with cannulae aimed at the dlPAG were re-exposed to a chamber where they had received footshocks 48 h before. Fifteen minutes before the test, the animals received a first intra-dlPAG injection of vehicle or AM251, a CB1 receptor antagonist (100 pmol/200 nl), followed 5 min later by vehicle, AEA (5 pmol/200 nl) or AM404 (50 pmol/200 nl). Freezing and cardiovascular responses were recorded for 10 min.
RESULTS: Freezing and cardiovascular responses were reduced by administration of either AEA or AM404 into the dlPAG before re-exposition to the aversively conditioned context. These effects were abolished when the animals were locally pretreated with AM251. The latter drug, even at a higher dose (300 pmol), was ineffective when administered alone into the dlPAG.
CONCLUSION: The results suggest that facilitation of endocannabinoid-mediated neurotransmission in the dlPAG, through activation of local CB1 receptors, attenuates the expression of contextual fear responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446325     DOI: 10.1007/s00213-008-1156-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Involvement of medial prefrontal cortex neurons in behavioral and cardiovascular responses to contextual fear conditioning.

Authors:  L B M Resstel; S R L Joca; F G Guimarães; F M A Corrêa
Journal:  Neuroscience       Date:  2006-09-14       Impact factor: 3.590

Review 2.  Effects of excitatory amino acids and nitric oxide on flight behavior elicited from the dorsolateral periaqueductal gray.

Authors:  R M De Oliveira; E A Del Bel; F S Guimarães
Journal:  Neurosci Biobehav Rev       Date:  2001-12       Impact factor: 8.989

3.  Passive and active reactions to fear-eliciting stimuli.

Authors:  R J Blanchard; D C Blanchard
Journal:  J Comp Physiol Psychol       Date:  1969-05

4.  Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats.

Authors:  M L Molchanov; F S Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2001-11-29       Impact factor: 4.530

5.  Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear.

Authors:  Jasmeer P Chhatwal; Michael Davis; Kimberly A Maguschak; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

7.  Defensive behavior and hypertension induced by glutamate in the midbrain central gray of the rat.

Authors:  J E Krieger; F G Graeff
Journal:  Braz J Med Biol Res       Date:  1985       Impact factor: 2.590

8.  Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling.

Authors:  M Egertová; B F Cravatt; M R Elphick
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear.

Authors:  J E LeDoux; J Iwata; P Cicchetti; D J Reis
Journal:  J Neurosci       Date:  1988-07       Impact factor: 6.167

10.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

View more
  22 in total

1.  The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone.

Authors:  W M Olango; M Roche; G K Ford; B Harhen; D P Finn
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.

Authors:  Andrés Uribe-Mariño; Audrey Francisco; Maria Angélica Castiblanco-Urbina; André Twardowschy; Carlos José Salgado-Rohner; José Alexandre S Crippa; Jaime Eduardo Cecílio Hallak; Antônio Waldo Zuardi; Norberto Cysne Coimbra
Journal:  Neuropsychopharmacology       Date:  2011-09-14       Impact factor: 7.853

3.  Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.

Authors:  Thércia G Viana; Sara C Hott; Leonardo B Resstel; Daniele C Aguiar; Fabrício A Moreira
Journal:  Psychopharmacology (Berl)       Date:  2014-11-13       Impact factor: 4.530

4.  Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference.

Authors:  Matthew S Powers; Gustavo D Barrenha; Nate S Mlinac; Eric L Barker; Julia A Chester
Journal:  Psychopharmacology (Berl)       Date:  2010-09-14       Impact factor: 4.530

5.  Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia.

Authors:  Laura C Gregg; Kwang-Mook Jung; Jessica M Spradley; Rita Nyilas; Richard L Suplita; Andreas Zimmer; Masahiko Watanabe; Ken Mackie; István Katona; Daniele Piomelli; Andrea G Hohmann
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

6.  Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.

Authors:  Lindsay B Hough; Konstantina Svokos; Julia W Nalwalk
Journal:  Brain Res       Date:  2008-10-21       Impact factor: 3.252

7.  Involvement of endocannabinoid neurotransmission in the bed nucleus of stria terminalis in cardiovascular responses to acute restraint stress in rats.

Authors:  Lucas Gomes-de-Souza; Leandro A Oliveira; Ricardo Benini; Patrícia Rodella; Willian Costa-Ferreira; Carlos C Crestani
Journal:  Br J Pharmacol       Date:  2016-08-22       Impact factor: 8.739

8.  Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats.

Authors:  Daniele C Aguiar; Ana Luisa B Terzian; Francisco S Guimarães; Fabrício A Moreira
Journal:  Psychopharmacology (Berl)       Date:  2009-04-22       Impact factor: 4.530

9.  Modulation of fear memory by dietary polyunsaturated fatty acids via cannabinoid receptors.

Authors:  Daisuke Yamada; Jiro Takeo; Peter Koppensteiner; Keiji Wada; Masayuki Sekiguchi
Journal:  Neuropsychopharmacology       Date:  2014-02-12       Impact factor: 7.853

Review 10.  Developmental regulation of fear learning and anxiety behavior by endocannabinoids.

Authors:  T T-Y Lee; M N Hill; F S Lee
Journal:  Genes Brain Behav       Date:  2015-11-05       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.